PAX7 and myotonic dystrophy type 1: The positive effect of the normalization of GSK3β on DM1 phenotype in adult HSALR muscle, treated with lithium, was reproduced by the treatment of these mice with a non-ATP competitive inhibitor of GSK3, TDZD-8 (4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione or NP 01139) [31].TDZD-8 increased the number of activated myogenic satellite cells in the skeletal muscle of the treated HSALR mice, accompanied by the increase of a marker of myogenic satellite cells, transcription factor Pax-7 [31].